Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06495424 · ClinicalTrials.gov registry record
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
A clinical trial of Painful Diabetic Neuropathy and Peripheral Diabetic Neuropathy, sponsored by Averitas Pharma.
- Recruiting
- Registry status
- 150
- Enrollment target
- 14
- Study locations
NCT06495424 is a study of Painful Diabetic Neuropathy and Peripheral Diabetic Neuropathy that is actively recruiting participants, run by Averitas Pharma. The registered enrollment target is 150 participants, above the 102-participant average among 5 other Painful Diabetic Neuropathy trials with a reported enrollment target (47% higher). The trial reports 14 study locations across 7 states.
The verdict
NCT06495424, a study of Painful Diabetic Neuropathy and Peripheral Diabetic Neuropathy, is actively recruiting participants, sponsored by Averitas Pharma.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this post-market observational study is to provide real-world evidence to support the repeated use of QUTENZA in patients with PDPN and to evaluate the potential for pain and concomitant medication use reduction.
Conditions Studied
Interventions
- DRUG Capsaicin 8%
Study Locations (14)
California
- Pacific Research Institute - Lakeport
- Pacific Research Institute - Santa Rosa
- Pacific Research Institute - Santa Rosa
- Pacific Research Institute - Sonoma
Georgia
- Horizon Clinical Research - Gainesville
- Horizon Clinical Research - Jasper
- Horizon Clinical Research - Newnan
Pennsylvania
- Center for Interventional Pain and Spine - Bryn Mawr
- Center for Interventional Pain and Spine - Fort Washington
- Center for Interventional Pain and Spine - Lancaster
Delaware
- Center for Interventional Pain and Spine - Wilmington
Kentucky
- Iqra Research - Edgewood
New Jersey
- Curalta Clinical Trials - Oradell
Ohio
- Iqra Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06495424
The ClinicalTrials.gov registry entry for NCT06495424 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 5 other Painful Diabetic Neuropathy trials with a reported enrollment target (47% higher). The listed sponsor is Averitas Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Painful Diabetic Neuropathy appearing as the primary indexed condition, and to 1 intervention - of which Capsaicin 8% is the first listed.
NCT06495424 reports 14 study locations spanning 7 distinct geographic areas - top geographies include California, Georgia, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06495424 about?
NCT06495424 is a clinical study titled "Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy". The purpose of this post-market observational study is to provide real-world evidence to support the repeated use of QUTENZA in patients with PDPN and to evaluate the potential for pain and concomitant medication use reduction.
What is the current status of trial NCT06495424?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-03-14. Estimated completion is 2027-03.
What conditions does trial NCT06495424 study?
This clinical trial studies the following conditions: Painful Diabetic Neuropathy, Peripheral Diabetic Neuropathy.
What interventions are being tested in trial NCT06495424?
The interventions under investigation include: Capsaicin 8% (DRUG).
Who is sponsoring clinical trial NCT06495424?
This trial is sponsored by Averitas Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06495424 being conducted?
This trial has 14 study locations across California, Delaware, Georgia, Kentucky, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Painful Diabetic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy
RECRUITING · Phase 2
-
SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease
RECRUITING · NA
-
Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy
COMPLETED · Phase 2
-
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
COMPLETED · Phase 2
Explore more on PlainTrial
Painful Diabetic Neuropathy
All registered trials for this condition
Peripheral Diabetic Neuropathy
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.